1. Home
  2. URGN vs IMXI Comparison

URGN vs IMXI Comparison

Compare URGN & IMXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • IMXI
  • Stock Information
  • Founded
  • URGN 2004
  • IMXI 1994
  • Country
  • URGN United States
  • IMXI United States
  • Employees
  • URGN N/A
  • IMXI N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • IMXI Retail: Computer Software & Peripheral Equipment
  • Sector
  • URGN Health Care
  • IMXI Technology
  • Exchange
  • URGN Nasdaq
  • IMXI Nasdaq
  • Market Cap
  • URGN 463.2M
  • IMXI 374.8M
  • IPO Year
  • URGN 2017
  • IMXI N/A
  • Fundamental
  • Price
  • URGN $10.38
  • IMXI $10.89
  • Analyst Decision
  • URGN Strong Buy
  • IMXI Buy
  • Analyst Count
  • URGN 7
  • IMXI 7
  • Target Price
  • URGN $36.75
  • IMXI $20.60
  • AVG Volume (30 Days)
  • URGN 635.6K
  • IMXI 334.5K
  • Earning Date
  • URGN 05-12-2025
  • IMXI 05-07-2025
  • Dividend Yield
  • URGN N/A
  • IMXI N/A
  • EPS Growth
  • URGN N/A
  • IMXI 1.60
  • EPS
  • URGN N/A
  • IMXI 1.70
  • Revenue
  • URGN $90,398,000.00
  • IMXI $652,547,000.00
  • Revenue This Year
  • URGN $36.82
  • IMXI $2.91
  • Revenue Next Year
  • URGN $119.10
  • IMXI $4.67
  • P/E Ratio
  • URGN N/A
  • IMXI $6.39
  • Revenue Growth
  • URGN 9.29
  • IMXI N/A
  • 52 Week Low
  • URGN $8.94
  • IMXI $10.07
  • 52 Week High
  • URGN $20.70
  • IMXI $22.38
  • Technical
  • Relative Strength Index (RSI)
  • URGN 48.46
  • IMXI 35.00
  • Support Level
  • URGN $9.63
  • IMXI $10.07
  • Resistance Level
  • URGN $11.75
  • IMXI $12.67
  • Average True Range (ATR)
  • URGN 0.82
  • IMXI 0.53
  • MACD
  • URGN -0.02
  • IMXI -0.09
  • Stochastic Oscillator
  • URGN 32.90
  • IMXI 31.06

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About IMXI International Money Express Inc.

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

Share on Social Networks: